TCM
PBYI icon

Tekla Capital Management’s Puma Biotechnology PBYI Stock Holding History

Tekla Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-45,400
Closed -$3.42M – 152
2015
Q3 		$3.42M Buy
+45,400
New +$4.29M 0.12% 119

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Tekla Capital Management's PBYI Position: Q3 2020 in Review

Tekla Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2020, closing a stake of 71,340 shares — an estimated $744K sold.

Tekla Capital Management first reported a position in PBYI in Q2 2013 and held it in 24 quarters. The position peaked at $31.6M in Q2 2013. 128 funds tracked by Wall St. Rank hold PBYI as of Q3 2020.

  • Tekla Capital Management reported no remaining Puma Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Tekla Capital Management sold 71,340 Puma Biotechnology shares in Q3 2020, an estimated $744K.
  • Tekla Capital Management first reported a position in Puma Biotechnology in Q2 2013 and held it in 24 quarters.
  • Tekla Capital Management's Puma Biotechnology position peaked at $31.6M in Q2 2013.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.